Site search
2898 results for '' found
An Open-label Extension Study to Evaluate Safety and Tolerability of Sotatercept [MK-7962] Administered Using a Weight-banded Approach in Participants With Pulmonary Arterial Hypertension [PAH] o
An Open-label Extension Study to Evaluate Safety and Tolerability of Sotatercept [MK-7962] Administered Using a Weight-banded Approach in Participants With Pulmonary Arterial Hypertension [PAH] o
/
Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial Of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy and Administered as Maintenance Therapy in Adu
Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial Of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy and Administered as Maintenance Therapy in Adu
/
DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate [ANZUP1801]. A randomised phase 3 double-blind, placebo-controlled trial of adding darolutam
DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate [ANZUP1801]. A randomised phase 3 double-blind, placebo-controlled trial of adding darolutam
/
Phase III, multicentre, randomised, double-blinded, placebo-controlled, MAMS trial of SpironolacTone and famciclOvir in the treatment of Progressive MS to prevent disability progression (STO
Phase III, multicentre, randomised, double-blinded, placebo-controlled, MAMS trial of SpironolacTone and famciclOvir in the treatment of Progressive MS to prevent disability progression (STO
/
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Subcutaneous Tarlatamab in Subjects with Extensive Stage Small Cell Lung Cancer [DeL
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Subcutaneous Tarlatamab in Subjects with Extensive Stage Small Cell Lung Cancer [DeL
/
A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Recurrent or Metastatic PD-L1+ Head and N
A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Recurrent or Metastatic PD-L1+ Head and N
/
A Clinical Evaluation of the Efemoral Vascular Scaffold System [EVSS] for the Treatment of Patients with Symptomatic Peripheral Vascular Disease from Stenosis or Occlusion of the Femoropopliteal
A Clinical Evaluation of the Efemoral Vascular Scaffold System [EVSS] for the Treatment of Patients with Symptomatic Peripheral Vascular Disease from Stenosis or Occlusion of the Femoropopliteal
/
SatisfACtion: A Phase I/II, open-label, multi-center study of [225Ac]Ac-PSMA-R2 in men with metastatic hormone sensitive prostate cancer (mHSPC) and in men with heavily pre-treated PSMA positive
SatisfACtion: A Phase I/II, open-label, multi-center study of [225Ac]Ac-PSMA-R2 in men with metastatic hormone sensitive prostate cancer (mHSPC) and in men with heavily pre-treated PSMA positive
/
A Phase II, randomized, open-label, multi-center study of JSB462 (luxdegalutamide) in combination with lutetium (177Lu) vipivotide tetraxetan in adult male patients with PSMA-positive metastatic
A Phase II, randomized, open-label, multi-center study of JSB462 (luxdegalutamide) in combination with lutetium (177Lu) vipivotide tetraxetan in adult male patients with PSMA-positive metastatic
/